OverviewSuggest Edit

BioCorRx Inc. operates alcoholism rehabilitation and treatment centers in California. The company distributes and licenses BioCorRx Recovery Program for the treatment of alcoholism and opioid addiction consisting of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with a counseling/life coaching program, including sessions from specialized life coaches and/or counselors. Its program is primarily used by independently owned and licensed clinics.
TypePublic
Founded2008
HQAnaheim, US
Websitebiocorrx.com

Latest Updates

Employees (est.) (Sept 2017)5
Revenue (FY, 2019)$240.3 K(-36%)
Share Price (Sept 2020)$1.9
Cybersecurity ratingAMore

Key People/Management at BioCorRx

Kent Emry

Kent Emry

Director
Lourdes Felix

Lourdes Felix

President, CFO, COO, Director
Brady Granier

Brady Granier

CEO and Director
Balbir S. Brar

Balbir S. Brar

Senior VP of Drug Development
Tom Welch

Tom Welch

VP of Operations
Luisa Ingargiola

Luisa Ingargiola

Director
Show more

BioCorRx Office Locations

BioCorRx has offices in Anaheim and Santa Ana
Anaheim, US (HQ)
2390 E Orangewood Ave #575
Santa Ana, US
Santa Ana, CA 92705, USA
Show all (2)

BioCorRx Financials and Metrics

BioCorRx Revenue

BioCorRx's revenue was reported to be $240.26 k in FY, 2019
USD

Revenue (Q2, 2020)

33.7k

Gross profit (Q2, 2020)

6.2k

Gross profit margin (Q2, 2020), %

18.4%

Net income (Q2, 2020)

(738.5k)

EBIT (Q2, 2020)

(2.2m)

Market capitalization (22-Sept-2020)

10.2m

Closing stock price (22-Sept-2020)

1.9

Cash (30-Jun-2020)

1.5m

EV

9.3m
BioCorRx's current market capitalization is $10.2 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

701.8k657.3k376.7k240.3k

Revenue growth, %

(6%)(43%)

Cost of goods sold

81.7k

Gross profit

158.6k
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

167.6k134.2k210.5k147.6k147.7k246.4k78.6k65.3k66.0k46.6k36.9k33.7k

Cost of goods sold

23.4k166.7k8.0k20.6k2.8k30.4k22.3k22.9k27.5k

Gross profit

110.9k43.9k139.6k58.0k62.5k35.6k24.3k14.0k6.2k

Gross profit Margin, %

83%21%95%74%96%54%52%38%18%
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

BioCorRx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

BioCorRx Online and Social Media Presence

Embed Graph

BioCorRx News and Updates

BioCorRx Provides Business Update for the Second Quarter of 2020

Anaheim, CA - (NewMediaWire) - August 14, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2020. Brady Granier, CEO, and Director…

BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic

Anaheim, CA - (NewMediaWire) - May 22, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments.Brady Granier, CEO, and Director …

BioCorRx Offers Free Access to the UnCraveRx Mobile Platform for Weight Loss Management During COVID-19 Pandemic

Anaheim, CA - (NewMediaWire) - April 10, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRx™ App for a limited time. Anyone interested ca…

BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic

Anaheim, CA - (NewMediaWire) - April 7, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering substance use disorder (SUD) medical professionals free access to the BioCo…

BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic

Anaheim, CA - (NewMediaWire) - March 31, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments.Brady Granier, CEO, and Directo…

BioCorRx Announces Senior Management Promotions

Lourdes Felix Promoted to President
Show more

BioCorRx Frequently Asked Questions

  • When was BioCorRx founded?

    BioCorRx was founded in 2008.

  • Who are BioCorRx key executives?

    BioCorRx's key executives are Kent Emry, Lourdes Felix and Brady Granier.

  • How many employees does BioCorRx have?

    BioCorRx has 5 employees.

  • What is BioCorRx revenue?

    Latest BioCorRx annual revenue is $240.3 k.

  • What is BioCorRx revenue per employee?

    Latest BioCorRx revenue per employee is $48.1 k.

  • Who are BioCorRx competitors?

    Competitors of BioCorRx include Alpha Biopharma, International Isotopes and Orion Health.

  • Where is BioCorRx headquarters?

    BioCorRx headquarters is located at 2390 E Orangewood Ave #575, Anaheim.

  • Where are BioCorRx offices?

    BioCorRx has offices in Anaheim and Santa Ana.

  • How many offices does BioCorRx have?

    BioCorRx has 2 offices.